Skip to main content

Advertisement

Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: Low disease activity for up to 3 years after adalimumab discontinuation in patients with early rheumatoid arthritis: 2-year results of the HOPEFUL-3 Study

Fig. 4

Cumulative probability plots showing ΔmTSS. Comparison of the ADA continuation group and the ADA discontinuation group over 4 years (weeks 0–208) (a) and over 3 years (weeks 52–208) (b); comparison of the initial intensive therapy group and the standard therapy group over 4 years (weeks 0–208) (c) and over 3 years (weeks 52–208) (d); and comparison of the initial intensive therapy group and the standard therapy group over 4 years (weeks 0–208) in the ADA continuation group (e) and in the ADA discontinuation group (f). ADA Adalimumab, ΔmTSS Change in modified total Sharp score

Back to article page